PFE - Pfizer

-

$undefined

N/A

(N/A)

Pfizer NYSE:PFE Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Location: 66 Hudson Boulevard East, New York, NY, 10001-2192, United States | Website: https://www.pfizer.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

178.7B

Cash

17.32B

Avg Qtr Burn

N/A

Short % of Float

1.89%

Insider Ownership

0.06%

Institutional Own.

67.57%

Qtr Updated

03/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TALA + enzalutamide Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Approved

Update

Approved

Update

Approved

Update

PADCEV® Details
Urothelial carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

Oxbryta (Voxelotor) Details
SCD (Sickle Cell Disease)

Approved

Quarterly sales

Approved

Quarterly sales

ABRYSVO Details
Respiratory syncytial virus, Respiratory virus

Approved

Quarterly sales

Approved

Quarterly sales

LORBRENA® Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

ELREXFIO (elranatamab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

VELSIPITY Details
Ulcerative colitis

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

ABRYSVO Details
Respiratory syncytial virus, Respiratory virus

Approved

Quarterly sales

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Cancer, Metastatic colorectal cancer, Colorectal cancer

Approved

Quarterly sales

BRAFTOVI® + cetuximab & mFOLFOX6 Details
Metastatic colorectal cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Aztreonam-Avibactam (ATM-AVI) Details
Pneumonia, Bacterial infection, Intra-abdominal infections

NDA

Submission

Phase 3

Data readout

Phase 3

Data readout

IBRANCE (palbociclib) Details
Cancer, Breast cancer

Phase 3

Data readout

Sasanlimab + BCG Details
Non-muscle invasive bladder cancer

Phase 3

Update

Phase 3

Update

TUKYSA (Tucatinib) combo Kadcyla Details
Cancer, Solid tumor/s, Breast cancer

Phase 3

Update

Ponsegromab Details
Cancer, Cancer cachexia

Phase 3

Initiation

Troriluzole Details
Obsessive compulsive disorder

Phase 2/3

Data readout

Phase 2

Data readout

ADCETRIS® + pembrolizumab Details
Solid tumor/s, Melanoma, Non-small cell lung carcinoma

Phase 2

Data readout

Verdiperstat Details
Multiple System Atrophy

Failed

Discontinued

Troriluzole Details
Spinocerebellar Ataxia

Failed

Discontinued

Troriluzole Details
Alzheimer's disease

Failed

Discontinued

Failed

Discontinued

Verdiperstat Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Danuglipron Details
Obesity, Type 2 diabetes

Failed

Discontinued